Glenmark concludes study on COVID drug Favipiravir

By: |
September 15, 2021 2:57 PM

Results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects like weakness, gastritis, diarrhoea, vomiting etc were found to be mild in nature.

FavipiravirResults showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects like weakness, gastritis, diarrhoea, vomiting etc were found to be mild in nature. (Representational image: Reuters)

Drug firm Glenmark Pharmaceuticals on Wednesday said it has successfully completed its post-marketing surveillance study on Favipiravir in India. The study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients, Glenmark said in a statement.

Results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects like weakness, gastritis, diarrhoea, vomiting etc were found to be mild in nature. The time for fever resolution was 4 days, while the time for the clinical cure was 7 days, it added.

The study was conducted at thirteen sites – both government and private institutions – across Mumbai, Bangalore, Hyderabad, Nashik, Nagpur, and Trivandrum. It was conducted in patients in line with the approved indication of the drug, Glenmark said. The average age of patients in the study was 40 years, with women comprising 40 per cent and 60 per cent men, it added.

“This study was crucial as it examined the safety and efficacy of FabiFlu in real-world settings, where multiple variables can impact the results,” Glenmark Pharmaceuticals, Group Vice President & Head, India Formulations, Alok Malik said.

Despite these factors, the PMS study demonstrated FabiFlu’s consistent ability to provide symptomatic relief and improve clinical outcomes in patients with mild to moderate COVID-19, he added.

On June 19, 2020, Glenmark received restricted emergency use approval from India’s drug regulator for Favipiravir for the treatment of mild to moderate COVID-19, the company said. Shares of Glenmark Pharmaceuticals were trading at Rs 535.85 per scrip on BSE, up 0.81 per cent from its previous close.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Adherence to COVID-19-appropriate behaviour during festive season key to prevent 3rd wave: Experts
2Internal research of Instagram finds teens negatively impacted, develop suicidal tendencies
3COVID-19: Delhi records one death, 33 new cases